ARDX
ARDELYX, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.09
+0.00%Oct 13, 2026, 23:10 UTC
A class action lawsuit was filed against Ardelyx on behalf of investors who acquired its common stock during the stated class period.
Oct 12, 2026, 12:01 UTC
Ardelyx announced real-world analysis results showing significantly reduced gastrointestinal-related healthcare resource utilization after adults with IBS-C initiated IBSRELA.
Source:Oct 1, 2026, 11:25 UTC
Grabar Law Office announced an investigation into whether certain officers and directors of Ardelyx, Inc. breached their fiduciary duties owed to the company and its shareholders.
Source:Sep 30, 2026, 21:06 UTC
Robbins LLP announced a class action filed on behalf of investors who purchased Ardelyx, Inc. common stock between January 13, 2025 and August 6, 2026, alleging the company misled investors about the commercial performance and growth prospects of ISBRELA and XPHOZAH.
Source:Sep 30, 2026, 00:30 UTC
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Ardelyx, Inc. on behalf of investors who acquired Ardelyx common stock between January 13, 2025 and August 6, 2026.
Sep 21, 2026, 11:30 UTC
Ardelyx, Inc. was sued for securities law violations, with the DJS Law Group inviting affected investors to discuss their rights.
Sep 2, 2026, 06:02 UTC
Beam Therapeutics appointed Eric Foster as chief commercial officer.
Source:Aug 25, 2026, 23:50 UTC
Ardelux CFO Susan Hohenleitner sold 1,558 shares of ARDELYX common stock on August 21, 2026, in an automatic sell-to-cover transaction to satisfy tax withholding on RSU vesting, totaling approximately $6,009.
Source:Aug 25, 2026, 23:50 UTC
Joseph James Reilly, Senior Vice President and Chief Accounting Officer of Ardelyx, Inc., sold 3,982 shares of company stock for $15,358 on August 21, 2026, to cover withholding taxes upon vesting of restricted stock units.
Source:Aug 25, 2026, 23:45 UTC
James Parker Brady, Chief Human Resources Officer of Ardelyx, sold 15,136 shares of Ardelyx common stock on August 21, 2026, for a total value of $58,378, as part of an automatic sell-to-cover arrangement to cover withholding taxes upon RSU vesting.
Source:Aug 14, 2026, 14:07 UTC
SueWallSt notified investors of potential securities claims against Ardelyx, alleging that payer coverage restrictions caused an 18% drop in Ardelyx's share price on August 7, 2026.
Source:Aug 6, 2026, 22:05 UTC
Ardelyx reported second-quarter product revenue of $118 million, up 31% year-over-year, its largest quarterly total to date.
Aug 6, 2026, 22:04 UTC
Ardelyx lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased payer restrictions affecting patient access.